Myc tagging along the TRAIL to death receptor 5

Cell Cycle

Volumn 3, Issue 7, 2004, Pages 918-920

  Sheikh, M Saeed ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Apoptosis; Bax; DR5; Malignant transformation; Myc; Ras; TRAIL

Indexed keywords

ANTIBODY; CYTOKINE; DEATH RECEPTOR 4; DEATH RECEPTOR 5; MYC PROTEIN; ONCOPROTEIN; PROTEIN BAX; RAS PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; CANCER CELL; CANCER THERAPY; CELL DEATH; MALIGNANT TRANSFORMATION; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REVIEW;

EID: 13144269593     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.3.7.1012     Document Type: Review

References (23)

1. LeBlanc HN. Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003; 10:66-75.
2. Sheikh MS, Huang Y. Death receptors as targets of cancer therapeutics. Curr Cancer Drug Targets 2004; 4:97-104.
3. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309-19.
4. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104:155-62.
5. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5:157-63.
6. Wang Y, Engels IH, Knee DA, Nasoff M, Deveraux QL, Quon KC. Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell 2004; 5:501-12.
7. Grandori C, Cowley SM, James LP, Eisenman RN. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 2000; 16:653-99.
8. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene 1999; 18:3004-16.
9. Garte SJ. The c-myc oncogene in tumor progression. Crit Rev Oncog 1993; 4:435-49.
10. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992; 69:119-28.
11. Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2002; 2:764-76.
12. Nesterov A, Nikrad M, Johnson, M, Kraft, AS. Oncogenic Ras sensitizes normal human cells to tumor necrosis fector-a-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 2004; 64:3922-7.
13. Mitchell KO, Ricci MS, Miyashita T, Dicker DT, Jin Z, Reed JC, El-Deiry WS. Bax is a transcriptional target and mediator of c-myc-induced apoptosis. Cancer Res. 2000; 60:6318-25.
14. Burns TF, El-Deiry WS. Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach. J Biol Chem 2001; 276:37879-8S.
15. Deng Y, Lin Y, Wu X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev 2002; 16:33-45.
16. LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, ScKow P, Fong S, Schwall R, Sinicropi D, Ashkenazi A. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 2002; 8:274-81.
17. He Q, Luo X, Huang Y, Sheikh MS. Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells. Oncogene 2002; 21:6032-40.
18. He Q, Montalbano J, Corcoran C, Jin W, Huang Y, Sheikh MS. Effect of Bax deficiency on death receptor 5 and mitochondrial pathways during endoplasmic reticulum calcium pool depletion-induced apoptosis. Oncogene 2003; 22, 2674-9.
19. He Q, Huang Y, Sheikh MS. Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells. Oncogene 2004; 23:2554-8.
20. Wu GS, Burns TF, McDonald III ER, Jiang W, Meng R, Krantz ID, Kao G, Gan DD, Zhou J-Y, Muschel R, Hamilton SR, Spinner NB, Markowitz S, Wu G, El-Deiry WS. KILLER/DR5 is DNA damage-inducible p53-regulated death receptor gene. Nature Gen 1997; 17:141-3.
21. Sheikh MS, Burns TF, Huang Y, Wu GS, Amundson S, Brooks KS, Fornace AJ Jr, El-Deiry WS. p53-dependent and independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and TNFα. Cancer Res. 1998; 58:1593-8.
22. Nimmanapalli R, Perkins CL, Odando M, O'Bryan E, Nguyen D, Bhalla KN. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res 2001; 61:759-63.
23. Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang HJ. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 2000; 60:847-53.